Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
LifeMD and Noom complete the provider group alongside WeightWatchers Clinic and Calibrate
Aya Yamada (Saga University) for her assistance with this work
Contact your healthcare provider within 2448 hours if you experience: Persistent vomiting : Inability to keep down fluids for more than 24 hours, which may lead to dehydration Severe abdominal pain : Particularly sharp, constant pain in the upper abdomen that may radiate to the back, which could indicate pancreatitis Visual changes : Blurred vision or difficulty focusing, especially in patients with pre-existing diabetic retinopathy Signs of dehydration : Decreased urination, dark urine, dizziness upon standing, or extreme thirst Persistent diarrhea : Lasting more than 48 hours or accompanied by fever Pregnancy or planning pregnancy : Weight management formulations are contraindicated during pregnancy [1] [2] Seek immediate emergency care for: Severe allergic reactions : Difficulty breathing, throat swelling, widespread rash, or rapid heart rate Symptoms of pancreatitis : Severe, persistent abdominal pain (often radiating to the back), accompanied by nausea and vomiting Signs of gallbladder disease : Sudden severe pain in the right upper abdomen, particularly after eating fatty foods, with or without fever Symptoms of hypoglycemia (in patients taking insulin or sulfonylureas concurrently): Severe shakiness, confusion, loss of consciousness, or seizures Signs of intestinal obstruction : Severe abdominal distension, persistent inability to pass stool or gas, vomiting Symptoms of acute kidney injury : Markedly decreased urine output, swelling of legs or feet, especially with severe dehydration Thyroid-related symptoms : New lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath Additionally, contact your provider if you experience unexplained mood changes, depression, or suicidal thoughts
Drews-Botsch, E.W
In 2023, semaglutide accounted for 88.1% of new GLP-1 receptor agonist prescriptions compared to 10.3% for liraglutide
